stockrowUFP Technologies, Inc.
UFPT Healthcare Medical Devices
UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.
- Revenue
- +11.6%
- EPS
- +25.6%
- Free cash flow
- −35.8%
- Total debt
- −40.2%
Quarter to September 2026, against a year earlier
Follow UFPT
Alert me
UFP Technologies, Inc. (UFPT) EBITDA
UFP Technologies, Inc.'s EBITDA for fiscal 2025 was $111.5M, up 16.6% from $95.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $116.0M. Over the past ten years it has ranged from $16.6M (fiscal 2015) to $111.5M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 5 consecutive fiscal years. UFP Technologies, Inc. ranks 27th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $111.5M | 16.60% |
| FY2024 | $95.6M | 38.43% |
| FY2023 | $69.1M | 2.65% |
| FY2022 | $67.3M | 127.10% |
| FY2021 | $29.6M | 18.51% |
| FY2020 | $25.0M | (23.97%) |
| FY2019 | $32.9M | 19.81% |
| FY2018 | $27.4M | 58.37% |
| FY2017 | $17.3M | (3.04%) |
| FY2016 | $17.9M | 7.92% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $33.1M | 16.97% |
| Mar 2026 | $28.3M | 6.96% |
| Dec 2025 | $26.4M | (6.46%) |
| Sep 2025 | $28.3M | (2.74%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TMDX TransMedics Group, Inc. compare | $126.9M |
| NEOG Neogen Corporation compare | $116.5M |
| UFPT UFP Technologies, Inc. | $116.0M |
| INSP Inspire Medical Systems, Inc. compare | $33.2M |
| AXGN AxoGen, Inc. compare | −$4.1M |
| ESTA Establishment Labs Holdings Inc. compare | −$8.1M |
| ALMR Alamar Biosciences, Inc. compare | −$38.4M |
| BFLY Butterfly Network, Inc. compare | −$51.0M |
| NVCR NovoCure Limited compare | −$119.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on UFPT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement